The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632 · cited 2×
“Other potential liabilities of agonist activity at human 5-HT2A or 5-HT2B receptors include cardiac valvular disease (Connolly et al., 1997; Devereux, 1998; Fitzgerald et al., 2000; Rothman et al., 2000; Horowski et al., 2004; Roth, 2007) and possibly pulmonary hypertension (Abenhaim et al.”
BackgroundEating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors
Tecott, L. H., Sun, L. M., Akana, S. F., Strack, A. M., Lowenstein, D. H., Dallman, M. F., & Julius, D. (1995) · Nature · doi:10.1038/374542a0 · Cited by 1,274
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Multiple neural systems controlling food intake and body weight
Berthoud, H.-R. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(02)00014-3 · Cited by 725 · cited 1×
“5-HT2C receptors are distributed in brain areas associated with regulation of food intake, including the nucleus of the solitary tract, dorsomedial hypothalamus, paraventricular hypothalamic nucleus, and the amygdala (Berthoud, 2002).”
BackgroundRothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Drugs and Valvular Heart Disease
Roth, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068265 · Cited by 479 · cited 6×
“…of agonist activity at human 5-HT2A or 5-HT2B receptors include cardiac valvular disease (Connolly et al., 1997; Devereux, 1998; Fitzgerald et al., 2000; Rothman et al., 2000; Horowski et al., 2004; Roth, 2007) and possibly pulmonary hypertension (Abenhaim et al., 1996; Launay et al., 2002).”
BackgroundInfluentialNonogaki, K., Strack, A. M., Dallman, M. F., & Tecott, L. H. (1998) · Nature Medicine · doi:10.1038/2647 · Cited by 467
Possible Role of Valvular Serotonin 5-HT2B Receptors in the Cardiopathy Associated with Fenfluramine
Fitzgerald, L. W., Burn, T. C., Brown, B. S., Patterson, J. P., Corjay, M. H., Valentine, P. A., Sun, J.-H., Link, J. R., Abbaszade, I., Hollis, J. M., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26444-0 · Cited by 440
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension
Launay, J.-M., Hervé, P., Peoc'h, K., Tournois, C., Callebert, J., Nebigil, C. G., Etienne, N., Drouet, L., Humbert, M., Simonneau, G., et al. (2002) · Nature Medicine · doi:10.1038/nm764 · Cited by 433
Schreiber, R., Brocco, M., Audinot, V, Gobert, A., Veiga, S., & Millan, M. J. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09485-6 · Cited by 300
Reduced satiating effect of d -fenfluramine in serotonin 5-HT 2C receptor mutant mice
Vickers, S. P., Clifton, P. G., Dourish, C. T., & Tecott, L. H. (1999) · Psychopharmacology · doi:10.1007/s002130050952 · Cited by 291
Roth, B. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00019-9 · Cited by 287
Millan, M. J. (2005) · Therapies · doi:10.2515/therapie:2005065 · Cited by 283
Vickers, S. P., Dourish, C. T., & Kennett, G. A. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00063-6 · Cited by 202
Smith, B. M., Smith, J. M., Tsai, J. H., Schultz, J. A., Gilson, C. A., Estrada, S. A., Chen, R. R., Park, D. M., Prieto, E. B., Gallardo, C. S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm0709034 · Cited by 202
Self-citationRocha, B. A., Goulding, E. H., O'Dell, L. E., Mead, A. N., Coufal, N. G., Parsons, L. H., & Tecott, L. H. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-10039.2002 · Cited by 158
5-HT 2C receptor activation decreases appetite and body weight in obese subjects
Sargent, P. A., Sharpley, A. L., Williams, C., Goodall, E. M., & Cowen, P. J. (1997) · Psychopharmacology · doi:10.1007/s002130050407 · Cited by 153
Kennett, G. A., & Curzon, G. (1991) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1991.tb12369.x · Cited by 149
Clifton, P. G., Lee, M. D., & Dourish, C. T. (2000) · Psychopharmacology · doi:10.1007/s002130000504 · Cited by 147
The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment
Reynolds, G. P., Templeman, L. A., & Zhang, Z. J. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.019 · Cited by 143
Ouagazzal, A., Grottick, A. J., Moreau, J., & Higgins, G. A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00282-2 · Cited by 116
Self-citationEpilepsy and Obesity in Serotonin 5‐HT2C Receptor Mutant Mice
Heisler, L. K., Chu, H.-M., & Tecott, L. H. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10175.x · Cited by 116
Buckland, P. R., Hoogendoorn, B., Guy, C., Smith, S. K., Coleman, S. L., & O’Donovan, M. C. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.613 · Cited by 108
Sleep and Sleep Homeostasis in Mice Lacking the 5-HT2c Receptor
Frank, M. G. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00353-6 · Cited by 106
Dunlop, J., Sabb, A. L., Mazandarani, H., Zhang, J., Kalgaonker, S., Shukhina, E., Rizzo, S. J. S., Vogel, R. L., Stack, G., Schechter, L. E., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075382 · Cited by 103
SEROTONIN 5-HT2C RECEPTOR AGONISTS: POTENTIAL FOR THE TREATMENT OF OBESITY
Miller, K. J. (2005) · Molecular Interventions · doi:10.1124/mi.5.5.8 · Cited by 96
Smith, B. M., Smith, J. M., Tsai, J. H., Schultz, J. A., Gilson, C. A., Estrada, S. A., Chen, R. R., Park, D. M., Prieto, E. B., Gallardo, C. S., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.080 · Cited by 86
Self-citationCentral Serotonin2C Receptor: From Physiology to Pathology
Giovanni, G. D., Matteo, V. D., Pierucci, M., Benigno, A., & Esposito, E. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606778522113 · Cited by 85
5-HT2C Receptor Agonists as Potential Drugs for the Treatment of Obesity
Bickerdike, M. J. (2003) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026033452249 · Cited by 84
Lowered leptin slims immune response
Flier, J. S. (1998) · Nature Medicine · doi:10.1038/2619 · Cited by 83
5-Hydroxytryptamine 2C (5-HT2C) Receptor Agonists as Potential Antiobesity Agents
Nilsson, B. M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm058240i · Cited by 82
Obesity drugs in clinical development.
Halford, J. C. G. (2006) · PubMed · Cited by 79
Serotonergic 5-HT2C Receptors as a Potential Therapeutic Target for the Design Antiepileptic Drugs
Isaac, M. B. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053386980 · Cited by 70
The potential use of selective 5-HT2Cagonists in treating obesity
Smith, B. M., Thomsen, W. J., & Grottick, A. J. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.3.257 · Cited by 58
Self-citationBlanpain, C. (2003) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.09.015 · Cited by 57
Appetite Suppressants and Valvular Heart Disease
Devereux, R. B. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391109 · Cited by 52
Higgins, G. A., Ouagazzal, A., & Grottick, A. J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704082 · Cited by 51
Self-citationFunctions of serotonin in hypoxic pulmonary vascular remodeling
Esteve, J. M., Launay, J., Kellermann, O., & Maroteaux, L. (2007) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:47:1:33 · Cited by 50
Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats
Hayashi, A., Sonoda, R., Kimura, Y., Takasu, T., Suzuki, M., Sasamata, M., & Miyata, K. (2004) · Brain Research · doi:10.1016/j.brainres.2004.03.032 · Cited by 48
Long-term serotonin effects in the rat are prevented by terguride
Hauso, Ø., Gustafsson, B. I., Loennechen, J. P., Stunes, A. K., Nordrum, I. S., & Waldum, H. L. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.02.009 · Cited by 46
Effects of a High‐Fat Diet and Strain on Hypothalamic Gene Expression in Rats
Schaffhauser, A. O., Madiehe, A. M., Braymer, H. D., Bray, G. A., & York, D. A. (2002) · Obesity Research · doi:10.1038/oby.2002.161 · Cited by 45
Mouse Genetic Approaches to Feeding Regulation: Serotonin 5-HT2CReceptor Mutant Mice
Tecott, L. H., & Abdallah, L. (2003) · CNS Spectrums · doi:10.1017/s109285290001885x · Cited by 36
Cited by
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Urban, D. J., & Roth, B. L. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124803 · Cited by 668
Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561
Metadata
- Authors
- Thomsen, W. J., Grottick, A. J., Menzaghi, F., Reyes-Saldana, H., Espitia, S., Yuskin, D., Whelan, K., Martin, M., Morgan, M., Chen, W., Al-Shamma, H., Smith, B., Chalmers, D., & Behan, D.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 325
- Issue
- 2
- Pages
- 577-587
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2156407398
- Cited by
- 402
- References
- 45
- FWCI
- 14.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.